lorlatinib will reduce the extent or effect of ergotamine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Keep away from use of lorlatinib with CYP3A substrates, where by negligible focus modifications might bring about serious therapeutic failures on the substrate.This is more likely to take place from in